Paxil CR on the upswing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's Paxil CR has recaptured 41% of its previous new prescriptions since its late June relaunch, the firm says July 28. "We're up to 2.2% new Rx share," Pharmaceuticals President David Stout told investors during GSK's second quarter earnings call. Paxil CR Q2 sales dropped 75% to $42 mil. Part of GSK's relaunch efforts include a 30-day free trial program (1Pharmaceutical Approvals Monthly July 2005, In Brief)...